Health Care Technology
Company Overview of Molecular Health AG
Molecular Health AG, a biomedical company, offers a computational system that transforms molecular data into clinically actionable information to provide various cancer treatment options for cancer patients. The company offers TreatmentMAP, a treatment decision support solution that guides physicians and patients in the use of genetic, clinical, molecular, and efficacy data. Its solutions include TreatmentMAP-targeted panel, a test that includes various genetic variants that develop a treatment plan for newly diagnosed solid tumor cancer; and TreatmentMAP-whole exome, which analyzes various genes to identify generic variation against a patient’s normal gene set in the areas of difficult to t...
Founded in 2004
Key Executives for Molecular Health AG
Chief Executive Officer and President
President of Molecular Health Inc - USA
Compensation as of Fiscal Year 2015.
Molecular Health AG Key Developments
Molecular Health Signs Distribution Agreement with TestAnalytika for Latin American Region
Jun 8 15
Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting. TestAnalytika will begin to market and distribute Molecular Health's cancer treatment decision support product, TreatmentMAPTM, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later 2015. TestAnalytika is bringing innovative integrated insurance solutions to the Latin American region to provide patients with access to advanced molecular genomic treatment support. TestAnalytika will also support patients who prefer to prepay or self-pay for these services.
Molecular Health Appoints Rudi Schmidt as Executive Vice President of Corporate Communications & Public Affairs
Jan 8 15
Molecular Health announced that on 1 January 2015 Rudi Schmidt accepted the position of Executive Vice President of Corporate Communications & Public Affairs at the company. Schmidt comes from the Asklepios clinic group, where he was head of Communications and Marketing for nine years.
MolecularHealth Provides Unprecedented Reimbursement Support with RxAssistance
Aug 21 14
MolecularHealth announced an important new component of its TreatmentMAP(TM) offering in the United States, called MolecularHealth(TM) RxAssistance. This new service is a value-added benefit for patients and their doctors, providing a level of reimbursement support not previously seen in the molecular diagnostic industry. Unlike reimbursement services offered by other companies that only assess insurance options for the molecular diagnostic test itself, RxAssistance evaluates insurance options for the therapies recommended by its tests. RxAssistance is designed to help streamline the reimbursement process and provide physicians and patients with support and education about payer reimbursement for treatment options. Each patient's TreatmentMAP results report and insurance information is reviewed by MolecularHealth's reimbursement specialist, a Certified Professional Coder(R), prior to results being sent to the physician. Off-label or investigational products recommended for treatment are flagged and information is gathered, including the likelihood a payer will reimburse for the suggested treatments and any additional information that will be needed to receive reimbursement, such as a letter of medical necessity. RxAssistance has been integrated into TreatmentMAP's end-to-end offering and is currently included as a value-added component of all orders. When a physician receives a patient's results report, they also receive an accompanying RxAssistance report, providing information on pre-authorization, patient responsibility for co-pays and deductibles, letters of medical necessity, and step therapy requirements and/or medical benefit formularies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|